Neurogene Inc. has an updated ownership report from Redmile-affiliated investors. Redmile Group, LLC and its principal, Jeremy C. Green, each report beneficial ownership of 1,572,202 shares of common stock, representing 9.9% of the outstanding class, all held through investment vehicles they manage.
Redmile Biopharma Investments I, L.P. reports beneficial ownership of 812,033 shares, or 5.1% of the common stock. These positions include 160,003 shares issuable upon exercise of pre-funded warrants. The percentages are calculated using 15,801,901 shares outstanding as of May 8, 2026, plus the warrant shares. Voting and dispositive power is shared among the Redmile entities, and both Redmile and Jeremy Green disclaim beneficial ownership beyond their pecuniary interests.
Positive
None.
Negative
None.
Key Figures
Redmile Group beneficial ownership:1,572,202 sharesJeremy C. Green beneficial ownership:1,572,202 sharesRedmile Biopharma Investments I, L.P. ownership:812,033 shares+4 more
7 metrics
Redmile Group beneficial ownership1,572,202 sharesBeneficially owned common stock reported by Redmile Group, LLC
Jeremy C. Green beneficial ownership1,572,202 sharesBeneficially owned common stock reported by Jeremy C. Green
Redmile Biopharma Investments I, L.P. ownership812,033 sharesBeneficially owned common stock reported by Redmile Biopharma Investments I, L.P.
Ownership percentage Redmile Group/Jeremy Green9.9%Percent of Neurogene common stock class
Ownership percentage Redmile Biopharma Investments I, L.P.5.1%Percent of Neurogene common stock class
Shares underlying pre-funded warrants160,003 sharesCommon stock issuable upon exercise of pre-funded warrants
Shares outstanding baseline15,801,901 sharesCommon stock outstanding as of May 8, 2026
"that are or may be deemed beneficially owned by Redmile Group, LLC"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pre-funded warrantsfinancial
"160,003 shares of Common Stock issuable upon exercise of certain pre-funded warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
pecuniary interestfinancial
"disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest"
shared voting powerfinancial
"Shared Voting Power 1,572,202.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"Shared Dispositive Power 1,572,202.00"
FAQ
How many Neurogene Inc. (NGNE) shares does Redmile Group, LLC report owning?
Redmile Group, LLC reports beneficial ownership of 1,572,202 shares of Neurogene common stock. This represents 9.9% of the class, including shares held through managed investment vehicles and shares issuable upon exercise of pre-funded warrants.
What percentage of Neurogene Inc. (NGNE) does Jeremy C. Green beneficially own?
Jeremy C. Green reports beneficial ownership of 1,572,202 shares, or 9.9% of Neurogene’s common stock. These securities are held through Redmile-managed funds, and he disclaims ownership beyond his pecuniary interest in those securities.
How many Neurogene Inc. (NGNE) shares does Redmile Biopharma Investments I, L.P. hold?
Redmile Biopharma Investments I, L.P. reports beneficial ownership of 812,033 shares of Neurogene common stock. This stake equals 5.1% of the outstanding class, including 160,003 shares issuable upon exercise of pre-funded warrants it directly holds.
How is the Neurogene Inc. (NGNE) ownership percentage calculated in this Schedule 13G/A?
Ownership percentages are based on 15,801,901 shares of Neurogene common stock outstanding as of May 8, 2026, plus 160,003 shares issuable upon exercise of pre-funded warrants, as referenced from a Form 10-Q filing.
Do Redmile Group and Jeremy C. Green have sole voting power over Neurogene Inc. (NGNE) shares?
They report 0 shares with sole voting or dispositive power and 1,572,202 shares with shared voting and dispositive power. The shares are held by Redmile-managed funds, and they each disclaim beneficial ownership beyond their pecuniary interests.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)
Neurogene Inc.
(Name of Issuer)
Common Stock, $0.000001 par value
(Title of Class of Securities)
64135M105
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
64135M105
1
Names of Reporting Persons
Redmile Group, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,572,202.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,572,202.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,572,202.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The information in Item 4 relating to the shares of common stock, $0.000001 par value, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC and the calculation of the percent of such class of securities is incorporated by reference herein.
SCHEDULE 13G
CUSIP Number(s):
64135M105
1
Names of Reporting Persons
Jeremy C. Green
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,572,202.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,572,202.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,572,202.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green and the calculation of the percent of such class of securities is incorporated by reference herein.
SCHEDULE 13G
CUSIP Number(s):
64135M105
1
Names of Reporting Persons
Redmile Biopharma Investments I, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
812,033.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
812,033.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
812,033.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Redmile Biopharma Investments I, L.P. and the calculation of the percent of such class of securities is incorporated by reference herein.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Neurogene Inc.
(b)
Address of issuer's principal executive offices:
535 W 24th Street, 5th Floor, New York, NY 10011
Item 2.
(a)
Name of person filing:
Redmile Group, LLC
Jeremy C. Green
Redmile Biopharma Investments I, L.P.
(b)
Address or principal business office or, if none, residence:
Redmile Group, LLC
900 Larkspur Landing Circle, Suite 270
Larkspur, California 94939
Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001
Redmile Biopharma Investments I, L.P.
c/o Redmile Group, LLC
900 Larkspur Landing Circle, Suite 270
Larkspur, California 94939
(c)
Citizenship:
Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom
Redmile Biopharma Investments I, L.P.: Delaware
(d)
Title of class of securities:
Common Stock, $0.000001 par value
(e)
CUSIP No.:
64135M105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Redmile Group, LLC - 1,572,202 (1)
Jeremy C. Green - 1,572,202 (1)
Redmile Biopharma Investments I, L.P. - 812,033 (2)
(b)
Percent of class:
Redmile Group, LLC - 9.9% (3)
Jeremy C. Green - 9.9% (3)
Redmile Biopharma Investments I, L.P. - 5.1% (3)
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Redmile Group, LLC - 0
Jeremy C. Green - 0
Redmile Biopharma Investments I, L.P. - 0
(ii) Shared power to vote or to direct the vote:
Redmile Group, LLC - 1,572,202 (1)
Jeremy C. Green - 1,572,202 (1)
Redmile Biopharma Investments I, L.P. - 812,033 (2)
(iii) Sole power to dispose or to direct the disposition of:
Redmile Group, LLC - 0
Jeremy C. Green - 0
Redmile Biopharma Investments I, L.P. - 0
(iv) Shared power to dispose or to direct the disposition of:
Redmile Group, LLC - 1,572,202 (1)
Jeremy C. Green - 1,572,202 (1)
Redmile Biopharma Investments I, L.P. - 812,033 (2)
(1) Redmile's and Jeremy C. Green's beneficial ownership of the Issuer's Common Stock is comprised of (i) 1,412,199 shares of Common Stock and (ii) 160,003 shares of Common Stock issuable upon exercise of certain pre-funded warrants to purchase Common Stock (the "Warrants"). All of such shares of Common Stock and the Warrants are directly owned by certain investment vehicles, including Redmile Biopharma Investments I, L.P. ("RBI I"), for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as their investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any.
(2) RBI I may be deemed to beneficially own (i) 652,030 shares of Common Stock, and (ii) 160,003 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI I.
(3) Percentage based on: (i) 15,801,901 shares of Common Stock outstanding as of May 8, 2026, as reported in the Form 10-Q for the quarterly period ended March 31, 2026 filed with the SEC on May 12, 2026; plus (ii) 160,003 shares of Common Stock issuable upon exercise of the Warrants.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See the response to Item 4.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Redmile Group, LLC
Signature:
/s/ Jeremy C. Green
Name/Title:
Managing Member
Date:
08/14/2026
Jeremy C. Green
Signature:
/s/ Jeremy C. Green
Name/Title:
Jeremy C. Green
Date:
08/14/2026
Redmile Biopharma Investments I, L.P.
Signature:
/s/ Jeremy C. Green
Name/Title:
Managing Member of Redmile Group, LLC, Managing Member of Redmile Biopharma Investments I (GP), LLC, General Partner of Redmile Biopharma Investments
